Moberg Pharma
10.17
SEK
0 %
MOB
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
6 following
0%
0%
-43.03%
+4.58%
-65.62%
-33.09%
-70.58%
-88.62%
-82.98%
Moberg Pharma is a Swedish pharmaceutical company focused on the commercialization of proprietary medicines based on proven substances. The company mainly works in nail fungus, where Moberg Pharma is developing a new external treatment. The company has agreements with commercial partners on site in Europe and Asia, among other places. The head office is in Bromma.
Read moreMarket cap
486.94M SEK
Turnover
3.87M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
11/2
2025
Annual report '24
13/5
2025
Interim report Q1'25
22/5
2025
General meeting '24
ShowingAll content types
Moberg Pharma: New terbinafine supplier secured
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools